# Characterization of the vaginal microbiome of postmenopausal patients receiving chemoradiation for locally advanced cervical cancer

**Authors:** Brett A. Tortelli, Jessika Contreras, Stephanie Markovina, Li Ding, Kristine M. Wylie, Julie K. Schwarz

PMC · DOI: 10.1172/jci.insight.176839 · JCI Insight · 2025-02-04

## TL;DR

This study explores the vaginal microbiome in postmenopausal women with cervical cancer undergoing treatment, finding that certain bacteria like Fusobacterium may be linked to cancer recurrence.

## Contribution

This is the first study to characterize the vaginal microbiome in postmenopausal patients with locally advanced cervical cancer undergoing chemoradiation.

## Key findings

- Vaginal microbiomes in patients were diverse and dominated by anaerobes.
- Fusobacterium was more abundant in patients who experienced cancer recurrence.
- Microbial diversity and abundance before treatment did not predict disease recurrence.

## Abstract

The standard-of-care treatment of locally advanced cervical cancer includes pelvic radiation therapy with concurrent cisplatin-based chemotherapy and is associated with a 30%–50% failure rate. New prognostic and therapeutic targets are needed to improve clinical outcomes. The vaginal microbiome has been linked to the pathogenesis of cervical cancer, but little is known about the vaginal microbiome in locally advanced cervical cancer as it relates to chemoradiation. In this pilot study, we utilized 16S rRNA gene community profiling to characterize the vaginal microbiomes of 26 postmenopausal women with locally advanced cervical cancer receiving chemoradiation. Our analysis revealed diverse anaerobe-dominated communities whose taxonomic composition, diversity, or bacterial abundance did not change with treatment. We hypothesized that characteristics of the microbiome might correlate with treatment response. Pretreatment microbial diversity and bacterial abundance were not associated with disease recurrence. We observed a greater relative abundance of Fusobacterium in patients who later had cancer recurrence, suggesting that Fusobacterium could play a role in modifying treatment response. Taken together, this hypothesis-generating pilot study provides insight into the composition and dynamics of the vaginal microbiome, offering proof of concept for the future study of the microbiome and its relationship with treatment outcomes in locally advanced cervical cancer.

We characterize the vaginal microbiome of postmenopausal women with locally advanced cervical cancer undergoing chemoradiation.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Diseases:** cervical cancer (MONDO:0002974)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), cervical cancer (MESH:D002583)
- **Chemicals:** cisplatin (MESH:D002945)
- **Species:** Homo sapiens (human, species) [taxon 9606], Fusobacterium (genus) [taxon 848]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11949058/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11949058/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC11949058/full.md

---
Source: https://tomesphere.com/paper/PMC11949058